Clinical Trials
Clinical Trials
CIRT
Results from the CIRT study confirm safety and effectiveness of SIRT with Y-90 resin microspheres within the real-world setting and confirm findings from the earlier studies1-3
Results from the mCRC cohort1,2

Results from the HCC cohort1,3

Abbreviations:
HCC: Hepatocellular carcinoma ; mCRC: metastatic colorectal cancer ; ECOG PS: Eastern Cooperative Oncology Group - Performance Status ; APRI: AST to Platelet Ratio Index ; TACE: Transarterial chemoembolization ; BSA : Body surface area ; OS: Overall survival ; PFS: Progression-free survival ; REILD: Radioembolization-Induced Liver Disease
References:
1. Helmberger T et al. Cardiovasc Intervent Radiol 2021; 44: 21–35. 2. Schaefer N et al. Clin Colorectal Cancer 2022; doi: 10.1016/j.clcc.2022.09.002. 3. Kolligs et al. JHEP Reports 2022; 5:100633. doi: 10.1016/j.jhepr.2022.100633
SIR-Spheres® Y-90 resin microspheres are indicated for the treatment of unresectable hepatocellular carcinoma (HCC) or unresectable metastatic liver tumors from primary colorectal cancer (mCRC) in patients refractory to or intolerant of chemotherapy.
SIR-Spheres® is a registered trademark of Sirtex SIR-Spheres Pty Ltd.